Npe. Vermeulen et al., TOXICITY OF FOTEMUSTINE IN RAT HEPATOCYTES AND MECHANISM-BASED PROTECTION AGAINST IT, Chemico-biological interactions, 110(3), 1998, pp. 139-158
Folemustine is a relatively novel DNA-alkylating 2-chloroethyl-substit
uted N-nitrosourea (CENU) drug, clinically used for the treatment of d
isseminated malignant melanoma in different visceral and non-visceral
tissues. Thrombocytopenia has been observed in patients treated with f
otemustine and liver and renal toxicities as well. In this study. firs
tly the metabolism of fotemustine was investigated in vitro and second
ly the undesired cytotoxicity of fotemustine as well as different ways
of protection against it. In rat hepatocytes, chosen as a model syste
m, fotemustine was shown to cause lactate dehydrogenase (LDH) leakage,
glutathione (GSH) depletion, GSSG-formation and lipid peroxidation (L
PO). A reactive metabolite. DEP-isocyanate, is most likely responsible
for these undesired cytotoxic effects. Based on the observed cytotoxi
city mechanisms, chemoprotection with several sulfhydryl-containing nu
cleophiles and antioxidants was investigated. The sulfhydryl nucleophi
les, GSH, N-acetyl-L-cysteine (NAC) and glutathione isopropylester (GS
H-IP) protected almost completely against fotemustine-induced LDH-leak
age and LPO. NAC and GSH protected partly against fotemustine-induced
GSH-depletion. The antioxidant, vitamin E protected completely against
fotemustine-induced LPO, but only partly against fotemustine-induced
LDH-leakage and not against GSH-depletion. Ebselen, a peroxidase-mimet
ic organoselenium compound, did not show protective effects against th
e cytotoxicity of fotemustine, possibly because GSH is required for th
e bioactivation of ebselen. It is concluded that co-administration of
sulfhydryl nucleophiles, in particular NAC and GSH-IP, possibly in com
bination with antioxidants, such as vitamin E, are effective against t
he toxicity of fotemustine in vitro. It might, therefore, be worthwhil
e to investigate the cytoprotective potency of these agents against un
desired toxicities of fotemustine in vivo as well. (C) 1998 Elsevier S
cience Ireland Ltd. All rights reserved.